Abdulrahman Katib: Extended Low-Dose DOAC May Reduce VTE Recurrence
Abdulrahman Katib, Internal Medicine and Adult Thrombosis Consultant at King Faisal Specialist Hospital and Research Center, shared on LinkedIn about a recent article by Gregory Piazza et al, published in The New England Journal of Medicine:
“Not all ‘provoked VTE’ is low risk.
HI-PRO suggests low-dose extended DOAC may reduce recurrence in patients with ongoing risk.
Extended low-dose apixaban (2.5 mg BID) reduced recurrent VTE compared with placebo, with a reassuring bleeding profile.”
Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, and Samuel Z. Goldhaber
Read the Full Article on The New England Journal of Medicine
More posts about Abdulrahman Katib.
-
Feb 1, 2026, 13:26Mary Cushman: Association of Atrial Fibrillation with Risk of Incident Cognitive Impairment
-
Feb 1, 2026, 13:22Jeff June: The Stroke That Wasn’t New – Why ‘Cryptogenic’ Often Means Undetected
-
Feb 1, 2026, 13:11Panagiotis Doukas: Plasma Desmosine as a Biomarker of Increased Proteolytic Activity in the Aortic Wall
-
Feb 1, 2026, 12:54Pierpaolo Di Micco: Starting a New Era for Anticoagulant Treatments
-
Feb 1, 2026, 12:16Erwin Loh: Immunotherapy Reduces Plaque in Arteries of Mice
-
Feb 1, 2026, 12:06Ney Carter Borges: The Central Role of Endothelial Dysfunction in Cardiovascular Disease Progression
-
Feb 1, 2026, 12:05Causes of Anemia – A Quick Overview From Mahnoor Shah
-
Feb 1, 2026, 11:58Michael Makris: Moving Letter from Minnesota Physicians
-
Feb 1, 2026, 11:50Wolfgang Miesbach on The 1st Case of Secondary Malignancy Triggered by Integrated AAV